Skip to main content

Search

Reset all filters
721 Result(s)
Sort by

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
Animal Health Products

Animal Health Products

Our animal health products are powered by innovation, with an aim to provide advanced, preventive solutions. See our animal health products below.
Technologies

Technologies

We are expanding our global network of technology partners. Learn more about partnering with us.
Yamagata

Yamagata

With its location in the Yamagata prefecture (Higashine), this site focuses on the production & packaging of human pharmaceuticals for the Japanese market.
Targeting HER2 in cancer

Targeting HER2 in cancer

Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
Innovation in Oncology and Cancer Immunology

Innovation in Oncology and Cancer Immunology

Cancer research is one of the cornerstones of BI's research and has resulted in the launch of 2 products for the treatment of non-small cell lung cancer.
Family owned

Family owned

Did you know that Boehringer is still family-owned? Read this article to learn more about our culture. Check out our Careers Page for more talent insights!
Vienna

Vienna

Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Diversity

Diversity

At Boeheringer Ingelheim, we believe in a diverse working culture. Find out what our people like most about working with us.
Tomorrow leaders

Tomorrow leaders

We invest in our employees by giving them leadership training that enhances their skills and prepares them for future roles within the organization.
Something learnt

Something learnt

We know that to really thrive as a company, we have to help our teams to continue to grow in their careers. Here are some of things they have learnt at work.